Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992466 | 1.00 | MAOB (0.58) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL13754875 | 0.84 | NR4A2 (0.48) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL1564257 | 0.84 | NR4A2 (0.48) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL26363489 | 0.83 | MAOB (0.57) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL9756904 | 0.81 | ALDH1A1 (0.63) | MAOBCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL9756901 | 0.81 | ALDH1A1 (0.63) | MAOBCCNB2CDK1CDK4CCNB1 | |
| SCHEMBL7964667 | 0.78 | ALOX5 (0.56) | MAOBMAOAALOX5CYP3A4BCHE | |
| SCHEMBL14311058 | 0.77 | MAOB (0.50) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL28320282 | 0.77 | MAOB (0.50) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL19282141 | 0.76 | NQO1 (0.41) | CYP3A4KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-116003321-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115969853-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115721648-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-112174935-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-112409334-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| CN-112409334-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3497098-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| WO-2018172984-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| CN-102060758-B | Preparation method of 4-benzyloxy-pyridine-2-ketone | UNIV HANGZHOU NORMAL | 2012-12-05 | — | — | CN | disclosed |
| CN-102060758-B | Preparation method of 4-benzyloxy-pyridine-2-ketone | UNIV HANGZHOU NORMAL | 2012-12-05 | — | — | CN | disclosed |
| CN-102060758-A | Preparation method of 4-benzyloxy-pyridine-2-ketone | UNIV HANGZHOU NORMAL | 2011-05-18 | — | — | CN | disclosed |
| CN-102060758-A | Preparation method of 4-benzyloxy-pyridine-2-ketone | UNIV HANGZHOU NORMAL | 2011-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | MAOB 3802/4885MAOA 3843/4885CCNB2 4548/4885 |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | MAOB 275/4885MAOA 254/4885CCNB2 2906/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | MAOB 3849/4885MAOA 3824/4885CCNB2 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.